Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

3(60%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

60%

Ph phase_2

20%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(1)

Detailed Status

Recruiting2

Not yet recruiting1

Active, not recruiting1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (60.0%)

Phase 21 (20.0%)

Phase 31 (20.0%)

Trials by Status

not_yet_recruiting120%

active_not_recruiting120%

recruiting240%

completed120%

Recent Activity

3 active trials

Showing 5 of 5

not_yet_recruitingphase_3

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

NCT06088888

recruitingphase_2

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

NCT06453902

Clinical Trials (5)

Showing 5 of 5 trials

NCT07489755Phase 3

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

Not Yet Recruiting

NCT06697899Phase 1

TGRX-678 Phase I Oral Pharmacokinetic Study

Completed

NCT05434312Phase 1

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

Active Not Recruiting

NCT06088888Phase 1

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

Recruiting

NCT06453902Phase 2

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Recruiting

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5